Delta-Fly Pharma Completes Exercise Price Adjustment Clause Bond Purchase and Cancellation

TOKYO, Jul 31 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) completed the acquisition and cancellation of its Ninth and Eleventh Series Warrants with exercise price adjustment clauses as previously announced on July 22, 2026.

On July 29, 2026, Delta-Fly Pharma acquired all remaining warrants of the Ninth and Eleventh Series. Specifically, the company purchased 5,000 units of the Ninth Series warrants and 30,000 units of the Eleventh Series warrants. As of the same day, the total number of exercised warrants was 21,451 for the Eleventh Series and 5,000 for the Ninth Series.

The total cost for acquiring the Ninth Series warrants was ¥1.2 million per warrant at ¥232 each, while the Eleventh Series warrants were acquired at ¥478,744 per warrant at ¥56 each. All acquired warrants were subsequently canceled on July 31, 2026. Following the cancellation, there are now 0 outstanding warrants for both the Ninth and Eleventh Series.

Looking ahead, the company anticipates that the impact of this warrant acquisition and cancellation on its fiscal year 2027 performance will be minor.